nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—chronic obstructive pulmonary disease	0.342	0.577	CbGaD
Pomalidomide—CYP1A2—chronic obstructive pulmonary disease	0.25	0.423	CbGaD
Pomalidomide—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0422	0.209	CbGbCtD
Pomalidomide—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0343	0.17	CbGbCtD
Pomalidomide—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0232	0.115	CbGbCtD
Pomalidomide—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0221	0.11	CbGbCtD
Pomalidomide—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0197	0.0978	CbGbCtD
Pomalidomide—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.0193	0.0958	CbGbCtD
Pomalidomide—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0182	0.0905	CbGbCtD
Pomalidomide—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0116	0.0574	CbGbCtD
Pomalidomide—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0109	0.0542	CbGbCtD
Pomalidomide—Thalidomide—TNF—chronic obstructive pulmonary disease	0.00157	0.401	CrCbGaD
Pomalidomide—PTGS2—leg—chronic obstructive pulmonary disease	0.00133	0.172	CbGeAlD
Pomalidomide—CRBN—respiratory system—chronic obstructive pulmonary disease	0.00122	0.157	CbGeAlD
Pomalidomide—Thalidomide—CYP1A1—chronic obstructive pulmonary disease	0.00119	0.305	CrCbGaD
Pomalidomide—Thalidomide—CYP1A2—chronic obstructive pulmonary disease	0.00115	0.294	CrCbGaD
Pomalidomide—CRBN—bronchus—chronic obstructive pulmonary disease	0.001	0.129	CbGeAlD
Pomalidomide—CRBN—trachea—chronic obstructive pulmonary disease	0.000898	0.116	CbGeAlD
Pomalidomide—CRBN—lung—chronic obstructive pulmonary disease	0.000646	0.0833	CbGeAlD
Pomalidomide—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.0004	0.0516	CbGeAlD
Pomalidomide—Neuropathy peripheral—Salbutamol—chronic obstructive pulmonary disease	0.000399	0.00319	CcSEcCtD
Pomalidomide—Epistaxis—Montelukast—chronic obstructive pulmonary disease	0.000399	0.00318	CcSEcCtD
Pomalidomide—Urinary tract infection—Salbutamol—chronic obstructive pulmonary disease	0.000396	0.00316	CcSEcCtD
Pomalidomide—Neuropathy—Prednisolone—chronic obstructive pulmonary disease	0.000392	0.00313	CcSEcCtD
Pomalidomide—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.000389	0.00311	CcSEcCtD
Pomalidomide—Epistaxis—Salbutamol—chronic obstructive pulmonary disease	0.000384	0.00307	CcSEcCtD
Pomalidomide—Urinary tract disorder—Arformoterol—chronic obstructive pulmonary disease	0.000382	0.00306	CcSEcCtD
Pomalidomide—Urinary tract disorder—Formoterol—chronic obstructive pulmonary disease	0.000382	0.00306	CcSEcCtD
Pomalidomide—Oedema peripheral—Formoterol—chronic obstructive pulmonary disease	0.000382	0.00305	CcSEcCtD
Pomalidomide—Oedema peripheral—Arformoterol—chronic obstructive pulmonary disease	0.000382	0.00305	CcSEcCtD
Pomalidomide—Connective tissue disorder—Formoterol—chronic obstructive pulmonary disease	0.000381	0.00304	CcSEcCtD
Pomalidomide—Connective tissue disorder—Arformoterol—chronic obstructive pulmonary disease	0.000381	0.00304	CcSEcCtD
Pomalidomide—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.00038	0.00303	CcSEcCtD
Pomalidomide—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.00038	0.00303	CcSEcCtD
Pomalidomide—Anxiety—Aminophylline—chronic obstructive pulmonary disease	0.000376	0.003	CcSEcCtD
Pomalidomide—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.000375	0.00299	CcSEcCtD
Pomalidomide—Connective tissue disorder—Montelukast—chronic obstructive pulmonary disease	0.000373	0.00298	CcSEcCtD
Pomalidomide—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.000372	0.00297	CcSEcCtD
Pomalidomide—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.000371	0.00296	CcSEcCtD
Pomalidomide—Cough—Tiotropium—chronic obstructive pulmonary disease	0.000365	0.00291	CcSEcCtD
Pomalidomide—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.000361	0.00288	CcSEcCtD
Pomalidomide—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.000359	0.00287	CcSEcCtD
Pomalidomide—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.000359	0.00287	CcSEcCtD
Pomalidomide—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.000359	0.00287	CcSEcCtD
Pomalidomide—Infection—Aminophylline—chronic obstructive pulmonary disease	0.000359	0.00287	CcSEcCtD
Pomalidomide—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000358	0.00286	CcSEcCtD
Pomalidomide—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.000358	0.00286	CcSEcCtD
Pomalidomide—Arthralgia—Tiotropium—chronic obstructive pulmonary disease	0.000356	0.00284	CcSEcCtD
Pomalidomide—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.000355	0.00283	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.000353	0.00282	CcSEcCtD
Pomalidomide—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.000352	0.00281	CcSEcCtD
Pomalidomide—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000349	0.00279	CcSEcCtD
Pomalidomide—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000349	0.00279	CcSEcCtD
Pomalidomide—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000345	0.00275	CcSEcCtD
Pomalidomide—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000342	0.00273	CcSEcCtD
Pomalidomide—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000342	0.00273	CcSEcCtD
Pomalidomide—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000342	0.00273	CcSEcCtD
Pomalidomide—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00034	0.00271	CcSEcCtD
Pomalidomide—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.000339	0.00271	CcSEcCtD
Pomalidomide—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.000339	0.00271	CcSEcCtD
Pomalidomide—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.000339	0.00271	CcSEcCtD
Pomalidomide—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000339	0.00271	CcSEcCtD
Pomalidomide—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.000337	0.00269	CcSEcCtD
Pomalidomide—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.000337	0.00269	CcSEcCtD
Pomalidomide—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000334	0.00267	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Prednisolone—chronic obstructive pulmonary disease	0.000334	0.00267	CcSEcCtD
Pomalidomide—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.000332	0.00265	CcSEcCtD
Pomalidomide—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.000332	0.00265	CcSEcCtD
Pomalidomide—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000331	0.00265	CcSEcCtD
Pomalidomide—PTGS2—respiratory system—chronic obstructive pulmonary disease	0.000331	0.0427	CbGeAlD
Pomalidomide—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00033	0.00263	CcSEcCtD
Pomalidomide—Chills—Salbutamol—chronic obstructive pulmonary disease	0.000328	0.00262	CcSEcCtD
Pomalidomide—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000327	0.00261	CcSEcCtD
Pomalidomide—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.000326	0.0026	CcSEcCtD
Pomalidomide—Back pain—Formoterol—chronic obstructive pulmonary disease	0.000326	0.0026	CcSEcCtD
Pomalidomide—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.000324	0.00259	CcSEcCtD
Pomalidomide—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.000324	0.00259	CcSEcCtD
Pomalidomide—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000322	0.00257	CcSEcCtD
Pomalidomide—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.00032	0.00256	CcSEcCtD
Pomalidomide—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000318	0.00254	CcSEcCtD
Pomalidomide—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.000317	0.00254	CcSEcCtD
Pomalidomide—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000316	0.00252	CcSEcCtD
Pomalidomide—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000316	0.00252	CcSEcCtD
Pomalidomide—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000314	0.00251	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000311	0.00248	CcSEcCtD
Pomalidomide—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000309	0.00247	CcSEcCtD
Pomalidomide—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000308	0.00246	CcSEcCtD
Pomalidomide—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000308	0.00246	CcSEcCtD
Pomalidomide—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000306	0.00244	CcSEcCtD
Pomalidomide—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000298	0.00238	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000294	0.00235	CcSEcCtD
Pomalidomide—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000294	0.00235	CcSEcCtD
Pomalidomide—Cough—Formoterol—chronic obstructive pulmonary disease	0.000294	0.00235	CcSEcCtD
Pomalidomide—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000292	0.00233	CcSEcCtD
Pomalidomide—PTGS2—connective tissue—chronic obstructive pulmonary disease	0.000291	0.0376	CbGeAlD
Pomalidomide—Cough—Montelukast—chronic obstructive pulmonary disease	0.000288	0.0023	CcSEcCtD
Pomalidomide—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000287	0.00229	CcSEcCtD
Pomalidomide—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000287	0.00229	CcSEcCtD
Pomalidomide—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000286	0.00228	CcSEcCtD
Pomalidomide—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000286	0.00228	CcSEcCtD
Pomalidomide—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000286	0.00228	CcSEcCtD
Pomalidomide—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000286	0.00228	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000285	0.00228	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000285	0.00228	CcSEcCtD
Pomalidomide—Neuropathy—Prednisone—chronic obstructive pulmonary disease	0.000285	0.00228	CcSEcCtD
Pomalidomide—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000281	0.00225	CcSEcCtD
Pomalidomide—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.00028	0.00224	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000279	0.00223	CcSEcCtD
Pomalidomide—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000278	0.00222	CcSEcCtD
Pomalidomide—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000278	0.00222	CcSEcCtD
Pomalidomide—Infection—Formoterol—chronic obstructive pulmonary disease	0.000273	0.00218	CcSEcCtD
Pomalidomide—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000273	0.00218	CcSEcCtD
Pomalidomide—PTGS2—bronchus—chronic obstructive pulmonary disease	0.000272	0.0351	CbGeAlD
Pomalidomide—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000271	0.00216	CcSEcCtD
Pomalidomide—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.00027	0.00216	CcSEcCtD
Pomalidomide—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00027	0.00216	CcSEcCtD
Pomalidomide—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00027	0.00216	CcSEcCtD
Pomalidomide—Infection—Montelukast—chronic obstructive pulmonary disease	0.000268	0.00214	CcSEcCtD
Pomalidomide—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000267	0.00214	CcSEcCtD
Pomalidomide—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000267	0.00213	CcSEcCtD
Pomalidomide—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000267	0.00213	CcSEcCtD
Pomalidomide—PTGS2—smooth muscle tissue—chronic obstructive pulmonary disease	0.000267	0.0344	CbGeAlD
Pomalidomide—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000266	0.00213	CcSEcCtD
Pomalidomide—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000264	0.00211	CcSEcCtD
Pomalidomide—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000264	0.00211	CcSEcCtD
Pomalidomide—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000263	0.0021	CcSEcCtD
Pomalidomide—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000262	0.00209	CcSEcCtD
Pomalidomide—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000258	0.00206	CcSEcCtD
Pomalidomide—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000256	0.00204	CcSEcCtD
Pomalidomide—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000255	0.00204	CcSEcCtD
Pomalidomide—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000252	0.00202	CcSEcCtD
Pomalidomide—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000251	0.00201	CcSEcCtD
Pomalidomide—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000251	0.00201	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000251	0.002	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000251	0.002	CcSEcCtD
Pomalidomide—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000249	0.00199	CcSEcCtD
Pomalidomide—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000249	0.00199	CcSEcCtD
Pomalidomide—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000247	0.00198	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000246	0.00196	CcSEcCtD
Pomalidomide—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000245	0.00196	CcSEcCtD
Pomalidomide—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000245	0.00196	CcSEcCtD
Pomalidomide—PTGS2—trachea—chronic obstructive pulmonary disease	0.000245	0.0316	CbGeAlD
Pomalidomide—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000244	0.00195	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000243	0.00194	CcSEcCtD
Pomalidomide—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000241	0.00193	CcSEcCtD
Pomalidomide—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000239	0.00191	CcSEcCtD
Pomalidomide—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000238	0.0019	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000238	0.0019	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000238	0.0019	CcSEcCtD
Pomalidomide—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000237	0.00189	CcSEcCtD
Pomalidomide—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000237	0.00189	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000237	0.00189	CcSEcCtD
Pomalidomide—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000235	0.00188	CcSEcCtD
Pomalidomide—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000235	0.00188	CcSEcCtD
Pomalidomide—Pain—Formoterol—chronic obstructive pulmonary disease	0.000235	0.00188	CcSEcCtD
Pomalidomide—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000235	0.00188	CcSEcCtD
Pomalidomide—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000235	0.00188	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000233	0.00186	CcSEcCtD
Pomalidomide—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000232	0.00186	CcSEcCtD
Pomalidomide—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000232	0.00185	CcSEcCtD
Pomalidomide—Pain—Montelukast—chronic obstructive pulmonary disease	0.00023	0.00184	CcSEcCtD
Pomalidomide—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00023	0.00184	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000229	0.00183	CcSEcCtD
Pomalidomide—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000228	0.00182	CcSEcCtD
Pomalidomide—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000228	0.00182	CcSEcCtD
Pomalidomide—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000227	0.00181	CcSEcCtD
Pomalidomide—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000227	0.00181	CcSEcCtD
Pomalidomide—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000226	0.00181	CcSEcCtD
Pomalidomide—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000226	0.0018	CcSEcCtD
Pomalidomide—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000225	0.0018	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000224	0.00179	CcSEcCtD
Pomalidomide—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000224	0.00179	CcSEcCtD
Pomalidomide—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000222	0.00177	CcSEcCtD
Pomalidomide—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000222	0.00177	CcSEcCtD
Pomalidomide—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000218	0.00174	CcSEcCtD
Pomalidomide—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000218	0.00174	CcSEcCtD
Pomalidomide—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000217	0.00173	CcSEcCtD
Pomalidomide—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000215	0.00172	CcSEcCtD
Pomalidomide—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000215	0.00172	CcSEcCtD
Pomalidomide—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000215	0.00172	CcSEcCtD
Pomalidomide—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000214	0.00171	CcSEcCtD
Pomalidomide—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000214	0.00171	CcSEcCtD
Pomalidomide—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000213	0.0017	CcSEcCtD
Pomalidomide—CYP1A2—lung—chronic obstructive pulmonary disease	0.000212	0.0274	CbGeAlD
Pomalidomide—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000205	0.00164	CcSEcCtD
Pomalidomide—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000205	0.0264	CbGeAlD
Pomalidomide—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000203	0.00162	CcSEcCtD
Pomalidomide—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000203	0.00162	CcSEcCtD
Pomalidomide—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000203	0.00162	CcSEcCtD
Pomalidomide—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000202	0.00161	CcSEcCtD
Pomalidomide—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000201	0.0016	CcSEcCtD
Pomalidomide—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000199	0.00159	CcSEcCtD
Pomalidomide—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000197	0.00158	CcSEcCtD
Pomalidomide—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000197	0.00158	CcSEcCtD
Pomalidomide—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000195	0.00156	CcSEcCtD
Pomalidomide—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000195	0.00156	CcSEcCtD
Pomalidomide—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000194	0.00155	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000194	0.00155	CcSEcCtD
Pomalidomide—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000193	0.00154	CcSEcCtD
Pomalidomide—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000191	0.00153	CcSEcCtD
Pomalidomide—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000191	0.00152	CcSEcCtD
Pomalidomide—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000188	0.0015	CcSEcCtD
Pomalidomide—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000188	0.0015	CcSEcCtD
Pomalidomide—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000186	0.00149	CcSEcCtD
Pomalidomide—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000184	0.00147	CcSEcCtD
Pomalidomide—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000184	0.00147	CcSEcCtD
Pomalidomide—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000182	0.00145	CcSEcCtD
Pomalidomide—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000182	0.00145	CcSEcCtD
Pomalidomide—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000178	0.00142	CcSEcCtD
Pomalidomide—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000178	0.00142	CcSEcCtD
Pomalidomide—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000178	0.00142	CcSEcCtD
Pomalidomide—PTGS2—lung—chronic obstructive pulmonary disease	0.000176	0.0227	CbGeAlD
Pomalidomide—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000175	0.0014	CcSEcCtD
Pomalidomide—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000175	0.0014	CcSEcCtD
Pomalidomide—Rash—Formoterol—chronic obstructive pulmonary disease	0.000173	0.00139	CcSEcCtD
Pomalidomide—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000173	0.00139	CcSEcCtD
Pomalidomide—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000173	0.00138	CcSEcCtD
Pomalidomide—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000173	0.00138	CcSEcCtD
Pomalidomide—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000173	0.00138	CcSEcCtD
Pomalidomide—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000172	0.00138	CcSEcCtD
Pomalidomide—Headache—Formoterol—chronic obstructive pulmonary disease	0.000172	0.00138	CcSEcCtD
Pomalidomide—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000172	0.00138	CcSEcCtD
Pomalidomide—CYP1A2—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000172	0.00247	CbGpPWpGaD
Pomalidomide—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000172	0.00247	CbGpPWpGaD
Pomalidomide—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000172	0.00137	CcSEcCtD
Pomalidomide—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000172	0.00137	CcSEcCtD
Pomalidomide—PTGS2—Overview of nanoparticle effects—TNF—chronic obstructive pulmonary disease	0.000171	0.00246	CbGpPWpGaD
Pomalidomide—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000171	0.00137	CcSEcCtD
Pomalidomide—Rash—Montelukast—chronic obstructive pulmonary disease	0.00017	0.00136	CcSEcCtD
Pomalidomide—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.00017	0.00136	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL6—chronic obstructive pulmonary disease	0.000169	0.00242	CbGpPWpGaD
Pomalidomide—Headache—Montelukast—chronic obstructive pulmonary disease	0.000169	0.00135	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000166	0.00133	CcSEcCtD
Pomalidomide—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000165	0.00132	CcSEcCtD
Pomalidomide—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000164	0.00131	CcSEcCtD
Pomalidomide—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000164	0.00131	CcSEcCtD
Pomalidomide—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000164	0.00131	CcSEcCtD
Pomalidomide—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000163	0.00131	CcSEcCtD
Pomalidomide—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000163	0.00131	CcSEcCtD
Pomalidomide—ABCB1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	0.000163	0.00234	CbGpPWpGaD
Pomalidomide—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000163	0.0013	CcSEcCtD
Pomalidomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000161	0.00231	CbGpPWpGaD
Pomalidomide—Nausea—Montelukast—chronic obstructive pulmonary disease	0.00016	0.00128	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	0.000159	0.00228	CbGpPWpGaD
Pomalidomide—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000154	0.00123	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—TLR4—chronic obstructive pulmonary disease	0.000153	0.00219	CbGpPWpGaD
Pomalidomide—ABCB1—trachea—chronic obstructive pulmonary disease	0.000151	0.0195	CbGeAlD
Pomalidomide—ABCB1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	0.00015	0.00215	CbGpPWpGaD
Pomalidomide—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.00015	0.0012	CcSEcCtD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.000149	0.00213	CbGpPWpGaD
Pomalidomide—TNF—amb2 Integrin signaling—IL6—chronic obstructive pulmonary disease	0.000147	0.00211	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	0.000146	0.0021	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000144	0.00115	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	0.000143	0.00206	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	0.000143	0.00206	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IL1B—chronic obstructive pulmonary disease	0.000141	0.00202	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—chronic obstructive pulmonary disease	0.00014	0.00201	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—LEP—chronic obstructive pulmonary disease	0.000139	0.00199	CbGpPWpGaD
Pomalidomide—PTGS2—Overview of nanoparticle effects—IL6—chronic obstructive pulmonary disease	0.000138	0.00198	CbGpPWpGaD
Pomalidomide—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000138	0.0011	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—SERPINE1—chronic obstructive pulmonary disease	0.000138	0.00198	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—ALB—chronic obstructive pulmonary disease	0.000138	0.00197	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—GSTM1—chronic obstructive pulmonary disease	0.000137	0.00197	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TLR4—chronic obstructive pulmonary disease	0.000136	0.00195	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000136	0.00194	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.000135	0.00194	CbGpPWpGaD
Pomalidomide—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000135	0.00108	CcSEcCtD
Pomalidomide—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000134	0.00107	CcSEcCtD
Pomalidomide—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000133	0.00106	CcSEcCtD
Pomalidomide—TNF—IL23-mediated signaling events—IL6—chronic obstructive pulmonary disease	0.000131	0.00188	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—NOS2—chronic obstructive pulmonary disease	0.00013	0.00186	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—TGFB1—chronic obstructive pulmonary disease	0.000129	0.00184	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—LEP—chronic obstructive pulmonary disease	0.000129	0.00184	CbGpPWpGaD
Pomalidomide—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000127	0.00102	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	0.000127	0.00182	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—TGFB1—chronic obstructive pulmonary disease	0.000127	0.00182	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	0.000127	0.00181	CbGpPWpGaD
Pomalidomide—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000127	0.00181	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000123	0.000981	CcSEcCtD
Pomalidomide—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000123	0.00098	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	0.000122	0.00175	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—IL1B—chronic obstructive pulmonary disease	0.000122	0.00175	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.00012	0.00171	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—TLR4—chronic obstructive pulmonary disease	0.000119	0.00171	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	0.000119	0.00171	CbGpPWpGaD
Pomalidomide—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000119	0.000952	CcSEcCtD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	0.000119	0.00171	CbGpPWpGaD
Pomalidomide—CYP1A2—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000119	0.00171	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	0.000119	0.00171	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—IL6—chronic obstructive pulmonary disease	0.000119	0.0017	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	0.000117	0.00168	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	0.000116	0.00166	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—chronic obstructive pulmonary disease	0.000114	0.00163	CbGpPWpGaD
Pomalidomide—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000902	CcSEcCtD
Pomalidomide—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000899	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000112	0.000896	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	0.000112	0.00161	CbGpPWpGaD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000111	0.0016	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—CRP—chronic obstructive pulmonary disease	0.000111	0.00159	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.00011	0.000877	CcSEcCtD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000109	0.00157	CbGpPWpGaD
Pomalidomide—ABCB1—lung—chronic obstructive pulmonary disease	0.000109	0.014	CbGeAlD
Pomalidomide—Infection—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000859	CcSEcCtD
Pomalidomide—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000848	CcSEcCtD
Pomalidomide—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000105	0.00084	CcSEcCtD
Pomalidomide—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000836	CcSEcCtD
Pomalidomide—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000105	0.0015	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—CXCL8—chronic obstructive pulmonary disease	0.000104	0.00149	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	0.000103	0.00148	CbGpPWpGaD
Pomalidomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000102	0.00147	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	0.000102	0.00146	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—IL6—chronic obstructive pulmonary disease	0.000102	0.00145	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—SERPINE1—chronic obstructive pulmonary disease	0.000101	0.00145	CbGpPWpGaD
Pomalidomide—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000101	0.00145	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL1B—chronic obstructive pulmonary disease	9.96e-05	0.00143	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	9.87e-05	0.000788	CcSEcCtD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	9.86e-05	0.00141	CbGpPWpGaD
Pomalidomide—Dizziness—Prednisolone—chronic obstructive pulmonary disease	9.85e-05	0.000787	CcSEcCtD
Pomalidomide—Insomnia—Prednisone—chronic obstructive pulmonary disease	9.79e-05	0.000782	CcSEcCtD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	9.75e-05	0.0014	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	9.7e-05	0.00139	CbGpPWpGaD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—TGFB1—chronic obstructive pulmonary disease	9.69e-05	0.00139	CbGpPWpGaD
Pomalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	9.63e-05	0.00138	CbGpPWpGaD
Pomalidomide—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	9.5e-05	0.00136	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	9.49e-05	0.00136	CbGpPWpGaD
Pomalidomide—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	9.41e-05	0.000752	CcSEcCtD
Pomalidomide—Rash—Prednisolone—chronic obstructive pulmonary disease	9.4e-05	0.000751	CcSEcCtD
Pomalidomide—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	9.39e-05	0.00075	CcSEcCtD
Pomalidomide—Fatigue—Prednisone—chronic obstructive pulmonary disease	9.34e-05	0.000746	CcSEcCtD
Pomalidomide—Headache—Prednisolone—chronic obstructive pulmonary disease	9.34e-05	0.000746	CcSEcCtD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—chronic obstructive pulmonary disease	9.27e-05	0.00133	CbGpPWpGaD
Pomalidomide—Constipation—Prednisone—chronic obstructive pulmonary disease	9.26e-05	0.00074	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—CXCL8—chronic obstructive pulmonary disease	9.24e-05	0.00132	CbGpPWpGaD
Pomalidomide—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	9.19e-05	0.00132	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	9.04e-05	0.0013	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—chronic obstructive pulmonary disease	9.04e-05	0.0013	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—TP53—chronic obstructive pulmonary disease	9.02e-05	0.00129	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	8.92e-05	0.000713	CcSEcCtD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	8.87e-05	0.00127	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL1B—chronic obstructive pulmonary disease	8.86e-05	0.00127	CbGpPWpGaD
Pomalidomide—Nausea—Prednisolone—chronic obstructive pulmonary disease	8.85e-05	0.000707	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—LEP—chronic obstructive pulmonary disease	8.6e-05	0.00123	CbGpPWpGaD
Pomalidomide—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	8.56e-05	0.000684	CcSEcCtD
Pomalidomide—PTGS2—Selenium Micronutrient Network—SERPINE1—chronic obstructive pulmonary disease	8.53e-05	0.00122	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	8.53e-05	0.00122	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—ALB—chronic obstructive pulmonary disease	8.51e-05	0.00122	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	8.45e-05	0.00121	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TLR4—chronic obstructive pulmonary disease	8.42e-05	0.00121	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—MMP9—chronic obstructive pulmonary disease	8.36e-05	0.0012	CbGpPWpGaD
Pomalidomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	8.29e-05	0.00119	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IL6—chronic obstructive pulmonary disease	8.26e-05	0.00118	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	8.14e-05	0.00117	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—CXCL8—chronic obstructive pulmonary disease	8.1e-05	0.00116	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—NOS2—chronic obstructive pulmonary disease	8.01e-05	0.00115	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	7.98e-05	0.000637	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—chronic obstructive pulmonary disease	7.9e-05	0.00113	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—TP53—chronic obstructive pulmonary disease	7.81e-05	0.00112	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	7.81e-05	0.00112	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL1B—chronic obstructive pulmonary disease	7.77e-05	0.00111	CbGpPWpGaD
Pomalidomide—Asthenia—Prednisone—chronic obstructive pulmonary disease	7.77e-05	0.000621	CcSEcCtD
Pomalidomide—Pruritus—Prednisone—chronic obstructive pulmonary disease	7.66e-05	0.000612	CcSEcCtD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	7.61e-05	0.00109	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	7.48e-05	0.00107	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—chronic obstructive pulmonary disease	7.44e-05	0.00107	CbGpPWpGaD
Pomalidomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	7.43e-05	0.00106	CbGpPWpGaD
Pomalidomide—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	7.41e-05	0.000592	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	7.39e-05	0.00106	CbGpPWpGaD
Pomalidomide—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	7.33e-05	0.00105	CbGpPWpGaD
Pomalidomide—Dizziness—Prednisone—chronic obstructive pulmonary disease	7.16e-05	0.000572	CcSEcCtD
Pomalidomide—TNF—Developmental Biology—ADIPOQ—chronic obstructive pulmonary disease	7.12e-05	0.00102	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	7.09e-05	0.00102	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	6.93e-05	0.000993	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TGFB1—chronic obstructive pulmonary disease	6.89e-05	0.000987	CbGpPWpGaD
Pomalidomide—Vomiting—Prednisone—chronic obstructive pulmonary disease	6.88e-05	0.00055	CcSEcCtD
Pomalidomide—CYP1A2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	6.87e-05	0.000984	CbGpPWpGaD
Pomalidomide—Rash—Prednisone—chronic obstructive pulmonary disease	6.83e-05	0.000545	CcSEcCtD
Pomalidomide—Dermatitis—Prednisone—chronic obstructive pulmonary disease	6.82e-05	0.000545	CcSEcCtD
Pomalidomide—CYP1A2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	6.79e-05	0.000973	CbGpPWpGaD
Pomalidomide—Headache—Prednisone—chronic obstructive pulmonary disease	6.78e-05	0.000542	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—EGFR—chronic obstructive pulmonary disease	6.75e-05	0.000968	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—IL1B—chronic obstructive pulmonary disease	6.68e-05	0.000957	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	6.59e-05	0.000944	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	6.56e-05	0.00094	CbGpPWpGaD
Pomalidomide—Nausea—Prednisone—chronic obstructive pulmonary disease	6.43e-05	0.000514	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—TGFB1—chronic obstructive pulmonary disease	6.37e-05	0.000913	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—IL6—chronic obstructive pulmonary disease	6.33e-05	0.000907	CbGpPWpGaD
Pomalidomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	6.02e-05	0.000863	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	6e-05	0.00086	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—APIP—chronic obstructive pulmonary disease	5.89e-05	0.000845	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL6—chronic obstructive pulmonary disease	5.83e-05	0.000836	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CXCL8—chronic obstructive pulmonary disease	5.71e-05	0.000819	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TP53—chronic obstructive pulmonary disease	5.67e-05	0.000812	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	5.58e-05	0.0008	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	5.58e-05	0.0008	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL1B—chronic obstructive pulmonary disease	5.48e-05	0.000785	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	5.36e-05	0.000767	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	5.3e-05	0.00076	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	5.24e-05	0.000751	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	5.24e-05	0.00075	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TGFB1—chronic obstructive pulmonary disease	5.19e-05	0.000744	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL6—chronic obstructive pulmonary disease	5.19e-05	0.000744	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MMP9—chronic obstructive pulmonary disease	5.17e-05	0.000741	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	5.12e-05	0.000734	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	5.1e-05	0.000731	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—EGFR—chronic obstructive pulmonary disease	5.09e-05	0.000729	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	5.03e-05	0.000721	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	5.02e-05	0.00072	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	5.02e-05	0.00072	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	4.83e-05	0.000692	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—IL6—chronic obstructive pulmonary disease	4.8e-05	0.000688	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	4.78e-05	0.000685	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	4.78e-05	0.000685	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.76e-05	0.000682	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.69e-05	0.000673	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	4.68e-05	0.000671	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	4.59e-05	0.000658	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—chronic obstructive pulmonary disease	4.56e-05	0.000653	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL6—chronic obstructive pulmonary disease	4.55e-05	0.000652	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	4.53e-05	0.00065	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—LEP—chronic obstructive pulmonary disease	4.42e-05	0.000634	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	4.4e-05	0.000631	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.37e-05	0.000627	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	4.34e-05	0.000623	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.31e-05	0.000618	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—chronic obstructive pulmonary disease	4.27e-05	0.000612	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TGFB1—chronic obstructive pulmonary disease	4.26e-05	0.00061	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	4.2e-05	0.000602	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	4.18e-05	0.000599	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—EGFR—chronic obstructive pulmonary disease	4.18e-05	0.000598	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	4.16e-05	0.000596	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	4.15e-05	0.000595	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.15e-05	0.000594	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.09e-05	0.000586	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	4.06e-05	0.000582	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TNF—chronic obstructive pulmonary disease	3.98e-05	0.00057	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.9e-05	0.00056	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	3.89e-05	0.000557	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	3.87e-05	0.000555	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	3.86e-05	0.000553	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GC—chronic obstructive pulmonary disease	3.8e-05	0.000544	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.67e-05	0.000526	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.62e-05	0.000519	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.53e-05	0.000506	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—chronic obstructive pulmonary disease	3.51e-05	0.000502	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.38e-05	0.000484	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	3.34e-05	0.000478	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.33e-05	0.000477	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL6—chronic obstructive pulmonary disease	3.21e-05	0.00046	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.2e-05	0.000459	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	3.16e-05	0.000452	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.16e-05	0.000452	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	2.9e-05	0.000415	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	2.84e-05	0.000407	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.81e-05	0.000403	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.77e-05	0.000397	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	2.71e-05	0.000388	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	2.69e-05	0.000386	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MMP9—chronic obstructive pulmonary disease	2.66e-05	0.000381	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	2.57e-05	0.000369	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.5e-05	0.000359	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	2.39e-05	0.000342	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	2.38e-05	0.000342	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.38e-05	0.000341	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	2.24e-05	0.000321	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.21e-05	0.000317	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	2.19e-05	0.000314	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	2.15e-05	0.000308	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EGFR—chronic obstructive pulmonary disease	2.15e-05	0.000308	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.15e-05	0.000308	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HDAC2—chronic obstructive pulmonary disease	2.08e-05	0.000298	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.08e-05	0.000297	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	2.05e-05	0.000294	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GCLC—chronic obstructive pulmonary disease	2.05e-05	0.000294	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	2.01e-05	0.000289	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2e-05	0.000286	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—KL—chronic obstructive pulmonary disease	1.94e-05	0.000277	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	1.92e-05	0.000275	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.91e-05	0.000274	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CTGF—chronic obstructive pulmonary disease	1.87e-05	0.000268	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.72e-05	0.000247	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.71e-05	0.000244	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	1.69e-05	0.000242	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.66e-05	0.000238	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—IL6—chronic obstructive pulmonary disease	1.65e-05	0.000237	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.59e-05	0.000228	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.54e-05	0.000221	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.47e-05	0.000211	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.45e-05	0.000208	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ERBB3—chronic obstructive pulmonary disease	1.45e-05	0.000208	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.44e-05	0.000206	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.42e-05	0.000203	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.33e-05	0.00019	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.32e-05	0.000189	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.29e-05	0.000185	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.25e-05	0.00018	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.22e-05	0.000175	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOS2—chronic obstructive pulmonary disease	1.21e-05	0.000173	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.17e-05	0.000168	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	1.16e-05	0.000166	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.08e-05	0.000155	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	1.06e-05	0.000152	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.02e-05	0.000146	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SERPINE1—chronic obstructive pulmonary disease	1.02e-05	0.000146	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.01e-05	0.000144	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOS3—chronic obstructive pulmonary disease	9.73e-06	0.000139	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.37e-06	0.000134	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.06e-06	0.00013	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	8.96e-06	0.000128	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.88e-06	0.000127	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ALB—chronic obstructive pulmonary disease	8.52e-06	0.000122	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	8.18e-06	0.000117	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NOS3—chronic obstructive pulmonary disease	8.15e-06	0.000117	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.14e-06	0.000117	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.03e-06	0.000115	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.53e-06	0.000108	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.48e-06	0.000107	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.09e-06	0.000102	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TGFB1—chronic obstructive pulmonary disease	6.43e-06	9.22e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EGFR—chronic obstructive pulmonary disease	6.31e-06	9.04e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.28e-06	9e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.2e-06	8.88e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	6.04e-06	8.65e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	5.78e-06	8.28e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.77e-06	8.27e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.47e-06	7.84e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IL6—chronic obstructive pulmonary disease	4.85e-06	6.95e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	4.82e-06	6.91e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	4.61e-06	6.61e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	3.72e-06	5.33e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	3.56e-06	5.1e-05	CbGpPWpGaD
